Additional desensitization studies utilizing bortezomib and costimulation blockade (belatacept and anti-CD40 mAb) as dual targeting therapy of plasma cells and the germinal center response led to prolonged graft survival despite significant CMV infection and drug toxicity [64]. Here, CD40 is linked to cytomegalovirus infection.